JP2010511710A - 免疫性流産を低減するためのｉｌ−２７アゴニストの使用 - Google Patents

免疫性流産を低減するためのｉｌ−２７アゴニストの使用 Download PDF

Info

Publication number
JP2010511710A
JP2010511710A JP2009540269A JP2009540269A JP2010511710A JP 2010511710 A JP2010511710 A JP 2010511710A JP 2009540269 A JP2009540269 A JP 2009540269A JP 2009540269 A JP2009540269 A JP 2009540269A JP 2010511710 A JP2010511710 A JP 2010511710A
Authority
JP
Japan
Prior art keywords
subject
trimester
cells
agonist
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009540269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511710A5 (OSRAM
Inventor
オディール ドヴェルーニュ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2010511710A publication Critical patent/JP2010511710A/ja
Publication of JP2010511710A5 publication Critical patent/JP2010511710A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009540269A 2006-12-07 2007-12-05 免疫性流産を低減するためのｉｌ−２７アゴニストの使用 Pending JP2010511710A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86903506P 2006-12-07 2006-12-07
PCT/US2007/024869 WO2008070097A1 (en) 2006-12-07 2007-12-05 Use of il-27 agonists to reduce immune mediated abortion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012236373A Division JP2013018794A (ja) 2006-12-07 2012-10-26 免疫性流産を低減するためのｉｌ−２７アゴニストの使用

Publications (2)

Publication Number Publication Date
JP2010511710A true JP2010511710A (ja) 2010-04-15
JP2010511710A5 JP2010511710A5 (OSRAM) 2010-09-16

Family

ID=39185969

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009540269A Pending JP2010511710A (ja) 2006-12-07 2007-12-05 免疫性流産を低減するためのｉｌ−２７アゴニストの使用
JP2012236373A Pending JP2013018794A (ja) 2006-12-07 2012-10-26 免疫性流産を低減するためのｉｌ−２７アゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012236373A Pending JP2013018794A (ja) 2006-12-07 2012-10-26 免疫性流産を低減するためのｉｌ−２７アゴニストの使用

Country Status (6)

Country Link
US (1) US20100150862A1 (OSRAM)
EP (1) EP2091555A1 (OSRAM)
JP (2) JP2010511710A (OSRAM)
CA (1) CA2671697A1 (OSRAM)
MX (1) MX2009006091A (OSRAM)
WO (1) WO2008070097A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531057A (ja) * 2012-07-20 2015-10-29 マトリクスラブ イノーヴ 生殖補助における着床の成功を増大させる方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784807B2 (en) 2006-09-22 2014-07-22 St. Jude Children's Research Hospital Method of inhibiting regulatory T-cell activity by administering an antibody that inhibits interleukin 35
EP2470566A1 (en) * 2009-08-24 2012-07-04 St. Jude Children's Research Hospital Compositions and methods for potentiating interleukin-35
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
WO2011063198A2 (en) 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
CA2918196A1 (en) * 2013-04-11 2014-10-16 The Brigham And Women's Hospital, Inc. Methods and compositions of treating autoimmune diseases
US12404494B2 (en) 2019-10-15 2025-09-02 Spinalcyte, Llc Prevention of recurrent miscarriages through administration of fibroblasts and fibroblast-educated paternal cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830451A (en) * 1996-07-19 1998-11-03 Brigham & Women's Hospital, Inc. Haematopoietic cytokine Epstein Barr virus-induced protein
ES2405506T3 (es) * 2003-10-24 2013-05-31 Nora Therapeutics, Inc. Un método para obtener datos útiles en la identificación de un paciente con riesgo de tener dificultad de llevar a término un embarazo

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531057A (ja) * 2012-07-20 2015-10-29 マトリクスラブ イノーヴ 生殖補助における着床の成功を増大させる方法

Also Published As

Publication number Publication date
CA2671697A1 (en) 2008-06-12
US20100150862A1 (en) 2010-06-17
JP2013018794A (ja) 2013-01-31
EP2091555A1 (en) 2009-08-26
MX2009006091A (es) 2009-08-18
WO2008070097A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
JP2013018794A (ja) 免疫性流産を低減するためのｉｌ−２７アゴニストの使用
Kanai et al. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease
JP4638876B2 (ja) Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
RU2426742C2 (ru) Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
ES2602581T3 (es) Anticuerpo monoclonal anti-LAG-3 citotóxico y su uso en el tratamiento o prevención del rechazo de órganos trasplantados y enfermedad autoinmunitaria
JP2020200346A (ja) 腫瘍療法のためのｉｌ−１２とｔ細胞阻害分子遮断薬とを含む医薬組成物
AU2005231478C1 (en) Modulation of NKG2D
JP2010518873A (ja) アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
KR20020084842A (ko) Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA129672C2 (uk) Антитіло до trem-1 та його застосування
JP2010235621A (ja) リンホトキシン（ｌｔ）経路のインヒビターを使用する濾胞性リンパ腫の処置
JP2021531813A (ja) キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用
US8795656B2 (en) Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody
JP2016540506A (ja) 新規ｂ細胞サイトカインの同定
CA2692282A1 (en) Regulatory t cells in adipose tissue
CA2584690A1 (en) Pif peptides biologic activities, site of action, and the antibody to detect pif
ZA200509143B (en) GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
JP2022523554A (ja) Ｔ細胞受容体及びその使用方法
US20080248011A1 (en) Methods for Isolating Monocytes
JP2021511054A (ja) Ｈｐｖ免疫療法
JP2024522349A (ja) Ｃ－ｘ－ｃモチーフケモカイン受容体６（ｃｘｃｒ６）結合分子及びその使用方法
JP2022523971A (ja) Ｔ細胞受容体及びその使用方法
WO2005115456A2 (en) METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY
CN101379087A (zh) 用于治疗与细胞因子信号传导相关的疾病和病症、牵涉与il-22和il-22r结合的抗体的组合物和方法
WO2021085295A1 (ja) 免疫応答抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120309

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121026